INTRODUCTION

With the increasing of cases of COVID-19 pneumonia around the world, reports recently revealed that kidney transplant recipients (KTRs) are more likely to be infected with SARS-CoV-2 under the same exposure conditions because of long-term immunosuppressive therapy. Large-scale reports found that the mortality rate of KTRs infected with SARS-CoV-2 was 24%-28%, significantly higher than that of nontransplant patients (1.4%-4.3%).

Abstract

There is no consensus on immunosuppression management for kidney transplant recipients (KTRs) with SARS-CoV-2 pneumonia. Therefore, we conducted a search in English database from October 2019 to July 2020 and extracted data from cases with treatment details worldwide, and total of 41 recipients with a median age of 50 years were enrolled in this study. Most of them were males (75.8%). The most common presenting symptoms were fever (80.5%), cough (63.4%), and fatigue (41.5%). Patients were classified into three catalogs according to severity of pneumonia: 17 (41.5%) were mild, 15 (36.6%) severe, and 9 (21.9%) critical disease. Laboratory tests revealed that serum creatinine of critical patients was significantly higher than that of mild or severe patients. 68.3% received oxygen support; all patients received antiviral therapy, and 15 (36.6%) recipients were additionally treated with intravenous immunoglobulin and interferon-α. 19.5% of patients maintained immunosuppressive therapy; 36.6% suspended antimetabolite; and 43.9% only treated with corticosteroid. Six (14.6%) patients died (severe: 2, critical: 4); high creatinine with low lymphocyte count was the biggest challenge of immunosuppression management. In all, it is necessary to pay close attention to renal function and lymphocyte count in KTRs infected with COVID-19 and choose appropriate medication programs according to the specific situations.

KEYWORDS

COVID-19, immunosuppression management, kidney transplant recipient
lymphocytopenia, and lymphocytopenia was related to the severity of patients.\cite{3,4} Therefore, reduction or cessation of immunosuppressants seems to contribute to the increase of lymphocytes in KTRs infected with SARS-CoV-2. However, reducing the usage of immunosuppressants increased the risk of kidney rejection. So far, there is no clear consensus to manage immunosuppressive therapy. Therefore, how to manage immunosuppressive therapy has become a crucial problem in KTRs with COVID-19.

In this review, we conducted a search in English database and extracted data from cases with treatment details worldwide and analyzed the relationship between the immunosuppressive regimen and the relevant indicators of KTRs with COVID-19, to provide an effective treatment plan for KTRs with SARS-CoV-2 pneumonia.

2 | MATERIALS AND METHODS

We carried out an electronic search in Medline (PubMed interface), Scopus, and Web of Science, using the keywords "COVID-19" OR "2019-nCoV" OR "SARS-CoV-2" OR "coronavirus 2019," AND "Transplant" OR "transplantation" OR "transplant recipients," AND "kidney" OR "renal," between October 1, 2019, and July 1, 2020. The reference list of all identified documents was scrutinized with the aim of identifying additional potentially eligible studies. Selection criteria were as follows: (a) Adult KTRs were diagnosed with SARS-CoV-2 infection; (b) more than 3 months after kidney (single organ) transplantation; (c) specific drug regimens of immunosuppressant; and (d) explicit clinical outcome (recovery or death). All references were assessed and selected by two independent reviewers (Qianchao Hu and Zibiao Zhong), and data were extracted from each study. Any disagreements arising during the selection assessment were resolved by discussion and consensus.

Information on sex, age, severity, renal function, lymphocyte number, immunosuppressant adjustment program, and clinical results of these 41 patients were collected and systematically reviewed the specific adjustment program of immunosuppressant in KTRs infected with SARS-CoV-2.

Statistical analysis was performed with SPSS V.17.0 software (IBM). Categorical data were presented as proportions, and continuous data were presented as means and SDs. Differences in proportions were tested by the chi-square test. The continuous variables with a normal distribution were tested using Student's t-test or analysis of variance test, and the continuous variables with a skewed distribution were tested using Mann-Whitney U test or the Kruskal-Wallis analysis. For all statistical tests, P < .05 was significant.

3 | RESULTS

3.1 | Clinical characteristics of all patients

A total of 21 reports were screened,\cite{5-25} and 41 KTRs with laboratory-confirmed COVID-19 were enrolled.

Among these 41 cases, 31 (75.61%) were males and 10 (24.39%) were females. The median age was 50 (IQR: 37, 64) years. The common clinical symptoms of these patients included fever (80.5%), cough (63.4%), and fatigue (41.5%). Some of them had gastrointestinal symptoms (21.9%) and conjunctivitis (2.5%). The time from onset to admission was 8.4 (CI 5.5-11.3) days; 6 (14.6%) patients died during hospitalization while 35 survived. In addition, 31 (75.6%) patients received triple maintenance immunosuppressive therapy with calcine inhibitors (CNI) (tacrolimus or cyclosporin A), antimetabolites (mycophenolate mofetil or mycophenolic acid), and corticosteroids (prednisone or methylprednisolone). 1 (2.4%) special case used belatacept instead of CNI, and 9 (21.9%) received dual immunosuppressive therapy regimen (Table 1).

3.2 | Clinical features of different subtypes (Mild vs Severe vs Critical)

COVID-19 was classified according to the Guidelines for the Diagnosis and Treatment of COVID-19 (7th)\cite{26}. In a total of 41 cases, mild cases were identified in 17 (41.5%), severe cases in 15 (36.6%), and critical cases in 9 (21.9%). There were significant differences between the three groups in terms of age (P = .042), while no significant differences in admission time (P = .198) and hospital stay (P = .788; Table 2). The laboratory findings showed that there were no significant differences between the three groups in terms of lymphocyte count and C-reactive protein (CRP), while serum creatinine (Cr) in critical cases was significantly higher than mild or severe cases (Cr: 132.55 vs 163.17 vs 244.82, P < .024). And there was higher mortality in critical cases than other two subtypes (0% vs 13.3% vs 44.4%; Table 3).

3.3 | Treatments in different subtypes (Mild vs Severe vs Critical)

All patients received antiviral treatment, and common antiviral drugs were lopinavir/ritonavir, hydroxychloroquine (HCQ), oseltamivir, and umifenovir. Some patients additionally treated with intravenous immunoglobulin (IVIg, 34.1%) or interferon-α (IFN-α, 9.8%). 68.3% patients received oxygen support. From Table 4, 35.5% mild cases received oxygen therapy, while in other subtypes the proportion reached to 93.3% and 88.9%, respectively.

As for the adjustment of immunosuppression, approach A: maintained on immunosuppression; approach B: only antimetabolites were suspended; approach C: only maintained on corticosteroids. From Table 4, the application proportion of approach A treatment in different subtypes were 41.2% vs 6.7% vs 0, approach B were 29.4% vs 40% vs 44.4%, and approach C were 29.4% vs 53.3% vs 55.6%. The death rate of patient who applied approach A was 0, approach B was 13.3%, and approach C was 22.2% (Table 4).
| Case | Sex/Age | Major comorbidities | Immunosuppression regimen | Symptoms at presentation | Onset to admission (d) | Outcomes/d |
|------|---------|---------------------|---------------------------|--------------------------|------------------------|------------|
| Zhong, ZZ | M/48 | Peripheral blood tri-system reduction | Tac + MMF | Fever, cough, short of breath, fatigue | 45 | Recovery/60 |
| Zhu L | M/52 | - | Tac + MMF + Pred | Fever, fatigue, dyspnea, nausea, cough | 7 | Recovery/28 |
| Huang JF | M/58 | - | MMF + steroid | Fever, cough, shortness of breath | 3 | Death/40 |
| Wang JP | M/49 | DM, HTN | CsA + MMF + Pred | Fever and respiratory symptoms | 7 | Recovery/14 |
| Marx, D | M/58 | - | Belatacept + MMF + Pred | Fever, mild dyspnea, and cough | 2 | Recovery/24 |
| Bartiromo, M | F/36 | - | Tac + MP | Gastrointestinal symptoms, dry cough | 5 | Recovery/9 |
| Zhang, H | M/38 | - | Tac + MMF + glucocorticoids | Fever, cough | 11 | Recovery/31 |
| Chu | F/37 | HTN | Tac + MMF + glucocorticoids | Fever, cough | 2 | Recovery/30 |
| Chen, S | M/38 | DM, HTN | Tac + MMF + glucocorticoids | Fever, cough, fatigue rhinorrhea | 5 | Recovery/27 |
| Seminari, E | M/50 | DM, HTN | Tac + MMF + Pred | Fever, poor appetite | 6 | Recovery/34 |
| Fernández-Ruíz M | M/78 | HTN, PC | Tac + Pred | Fever, shortness of breath | 1 | Death/5 |
| | M/71 | HTN | Tac + Pred + MPA | Fever, shortness of breath, cough, sore throat | 7 | Death/16 |
| Arpali, E | M/76 | HTN, obesity | MMF + Pred + Rapamycin | Fever, rhinorrhea | 3 | Recovery/13 |
| Bussalino, E | M/28 | TTM | Tac + MMF + Pred | Fever, malaise, sore throat, rhinorrhea | 2 | Recovery/14 |
| Ning, L | M/32 | HTN | Tac + MPA + Pred | Fever, dyspnea, dry cough | 3 | Recovery/15 |
| Zhu L | M/29 | HTN | MMF + CsA + MP | Fatigue, chills | 2 | Recovery/13 |
| | M/24 | - | Tac + MMF + Pred | Fever | 27 | Recovery/43 |
| | M/55 | CAD, AF, CHF | Tac + MMF + Pred | Cough, short of breath, fatigue | 5 | Recovery/48 |
| | M/29 | - | Tac + MMF + Pred | Fever, cough, short of breath, fatigue, diarrhea | 7 | Recovery/37 |
| | M/30 | HTN | Tac + MMF + Pred | Fever, cough, short of breath, fatigue | 21 | Recovery/37 |
| | M/50 | HTN | Tac + MMF + Pred | Fever, cough, short of breath, fatigue | 11 | Recovery/34 |
| | M/52 | HTN, CAD | Tac + MMF + Pred | Fever, cough, short of breath, fatigue | 7 | Recovery/20 |
| | M/49 | - | Tac + MMF | Fever, cough, short of breath, fatigue, diarrhea | 9 | Recovery/34 |

(Continues)
| Case | Sex/Age | Major comorbidities | Immunosuppression regimen | Symptoms at presentation | Onset to admission (d) | Outcomes/d |
|------|---------|----------------------|---------------------------|--------------------------|------------------------|------------|
| 25   | M/59    | HTN, HHD, COPD       | CsA + Mizoribine           | Fever, cough, short of breath, fatigue | 8                      | Death/14   |
| 26   | F/37    | HTN                  | Tac + MMF + Pred          | Fever, cough, short of breath, fatigue | 10                     | Recovery/31 |
| Kates, OS19 | M/54    | DM, HTN              | Tac + MMF                 | Fever, cough, vomiting, diarrhea, and dyspnea | 4                      | Recovery/13 |
| Kocak, B20 | F/28    | -                    | Tac + MMF + Pred          | Rhinorrhea, sore throat, malaise, fever | 2                      | Recovery/27 |
| 29   | F/56    | HTN                  | Tac + MMF + Pred          | Diarrhea, fever           | 3                      | Recovery/20 |
| Fung, M21  | M/47    | DM, HTN, CVD         | Tac + MMF + Pred          | Fever, cough, dyspnea, myalgia | 14                     | Recovery/39 |
| 30   | M/73    | CAD, DM, HTN         | Tac + MMF                 | Fever, cough, dyspnea, fatigue, diarrhea, anosmia, dysgeusia | 21                     | Recovery/34 |
| 31   | M/77    | CAD, sarcoidosis     | Tac + MMF + Pred          | Fever, Fatigue            | 2                      | Recovery/32 |
| 32   | F/71    | CAD, DM, CVD         | Tac + MMF + Pred          | Fever, cough, fatigue, anosmia, dysgeusia | 14                     | Recovery/21 |
| Cheng DR22 | M/48    | -                    | Tac + MMF + Pred          | Fever, chest tightness, asthenia | 13                     | Recovery/22 |
| 35   | F/65    | -                    | Tac + MMF + Pred          | Fever, cough, chest distress muscle ache weakness | 4                      | Recovery/41 |
| Tantisattamo, E23 | F/55    | Hyponatremia         | Tac + MMF+Pred            | Cough, dyspnea, headache, decreased appetite, nausea, fatigue. | 7                      | Recovery/12 |
| Chen, D24  | M/29    | -                    | Tac + MMF + Pred          | Fever, dry cough          | 2                      | Recovery/32 |
| Maritati, F25 | F/63    | HTN, obesity         | Tac + MPA + Pred          | -                        | -                      | Death/11   |
| 39   | M/73    | HTN, DM,             | Tac + MPA + Pred          | -                        | -                      | Recovery/34 |
| 40   | M/72    | HTN, HHD, obesity    | Tac + mTORi + Pred        | -                        | -                      | Death/48   |
| 41   | F/71    | HTN, ICD             | Tac + MPA + Pred          | -                        | -                      | Recovery/32 |

Abbreviations: AF, atrial fibrillation; CAD, coronary artery disease; CHF, chronic heart failure; COPD, chronic obstructive pulmonary disease; CsA, cyclosporin A; CVD, cerebrovascular disease; DM, diabetes mellitus; F, female; HHD, hypertensive heart disease; HTN, hypertension; ICD, ischemic cardiac disease; M, male; MMF, mycophenolate mofetil; MP, methylprednisolone; MPA, mycophenolic acid; mTORi, mTOR inhibitor; PC, prostatic carcinoma; Pred, prednisone; Tac, tacrolimus; TTM, transient thrombotic microangiopathy.
| Case | Severity | Renal function | Lymphocyte | IL-6 | CRP | Antiviral therapy | Oxygen support | Immunosuppression adjustment | Outcomes/d |
|------|----------|----------------|------------|------|-----|-------------------|----------------|---------------------------|------------|
| 1    | Mild     | Normal         | 0.5*10⁹/L  | 13.29 pg/mL | 101.79 mg/L | Oseltamivir, INF-a, IVIg | Nasal cannula | Tac (maintained) + MMF (cessation) + MP | Recovery/60 |
| 2    | Severe   | Cr: 139 μmol/L | 1.13*10⁹/L | 19.53 pg/mL | 54.0 mg/L | Umifenovir, INF-a, IVIg | Oxygen inhalation | Tac (reduction) + MMF and Pred (cessation) + MP | Recovery/28 |
| 3    | Critical | Renal failure  | 0.38*10⁹/L | -    | -   | Lopinavir/ritonavir | Mechanical ventilation | MMF (cessation) + MP | Death/40 |
| 4    | Mild     | Normal         | 0.59*10⁹/L | -    | 22.73 mg/L | Lopinavir/ritonavir, INF-a, | Nasal cannula | maintained on immunosuppression + MP | Recovery/14 |
| 5    | Mild     | Cr: 175 μmol/L | 0.5*10⁹/L | 29 ng/L | 88 mg/L | antiviral therapy | - | Belatacept and MMF (cessation) + Pred | Recovery/24 |
| 6    | Severe   | Cr: 202.5 μmol/L | normal | normal | 67 mg/L | Darunavir/cobicistat, HCQ | - | Tac (high level in the blood) + MP | Recovery/9 |
| 7    | Mild     | Cr: 98.0 μmol/L | 0.63*10⁹/L | -    | 6.68 mg/L | Oseltamivir or umifenovir | - | Tac (reduction) + MMF (cessation) + corticosteroid | Recovery/31 |
| 8    | Mild     | Cr: 137 μmol/L | 0.31*10⁹/L | -    | 9.77 mg/L | Oseltamivir or umifenovir, IVIg | - | Tac and MMF (cessation) + corticosteroid | Recovery/30 |
| 9    | Mild     | Cr: 135.4 μmol/L | 0.91*10⁹/L | -    | 33.72 mg/L | Oseltamivir or umifenovir | - | Maintained on immunosuppression | Recovery/27 |
| 10   | Severe   | Cr: 167.3 μmol/L | 0.43*10⁹/L | -    | 74.34 mg/L | Umifenovir, Ribavirin, IVIg | Oxygen inhalation | Tac (reduction) + MMF and Pred (cessation) + MP | Recovery/34 |
| 11   | Mild     | Cr: 145.9 μmol/L | 0.6*10⁹/L | 26.22 pg/mL | 1.86 mg/L | Lopinavir/ritonavir, HCQ | - | Maintained on immunosuppression | Recovery/13 |
| 12   | Critical | -              | -            | -    | -   | Lopinavir/ritonavir | High-flow oxygen therapy | Tac (reduction) + Pred | Death/5 |
| 13   | Severe   | -              | 7 pg/mL      | -    | -   | Lopinavir/ritonavir, HCQ, IVIg | CPAP | Tac (reduction) + MPA and Pred (cessation) + MP | Death/16 |
| 14   | Mild     | -              | -            | -    | -   | HCQ | CPAP | Pred and rapamycin (maintained) + MMF (cessation) + MP | Recovery/13 |
| 15   | Mild     | Cr: 81.3 μmol/L | 0.3*10⁹/L | -    | 5.7 ng/L | Oseltamivir | - | Maintained on immunosuppression | Recovery/14 |
| 16   | Severe   | Cr: 229.9 μmol/L | 17.8%      | 86.3 ng/L | 90 mg/L | HCQ, oseltamivir | Nasal cannula | Maintained on immunosuppression | Recovery/15 |
| 17   | Mild     | Cr: 102 μmol/L | 1.01*10⁹/L | -    | -   | Lopinavir/ritonavir + IVIg | - | Maintained on immunosuppression | Recovery/13 |
| 18   | Mild     | Cr: 198 μmol/L | normal       | -    | 30 mg/L | Antiviral therapy | Nasal cannula | Maintained on immunosuppression | Recovery/43 |
| 19   | Critical | Cr: 308 μmol/L | 0.3*10⁹/L | -    | 80.5 mg/L | Antiviral therapy, IVIg | Noninvasive ventilation | Tac (reduction) + MMF (cessation) + Pred | Recovery/48 |
| 20   | Severe   | Cr: 251 μmol/L | 0.47*10⁹/L | -    | 118 mg/L | Antiviral therapy | Nasal cannula | MMF (cessation) + Tac and Pred (maintained) + corticosteroid | Recovery/37 |
| Case | Severity | Renal (Cr) | Lymphocyte (x10^9/L) | IL-6 (pg/mL) | CRP (mg/L) | Antiviral therapy | Oxygen support | Immunosuppression adjustment | Outcomes |
|------|----------|------------|----------------------|--------------|-----------|-------------------|---------------|--------------------------|----------|
| 21   | Severe   | 219        | 0.61                  | 42.6         | +9.0      | Antiviral therapy | Nasal cannula | MMF and Tac (cessation)    | Recovery |
| 22   | Severe   | normal     | 0.42                  | 40           | +9.0      | Antiviral therapy | Nasal cannula | MMF and Tac (cessation)    | Recovery |
| 23   | Mild     | normal     | 0.39                  | 54           | +9.0      | Antiviral therapy | Nasal cannula | MMF and Tac (cessation)    | Recovery |
| 24   | Severe   | normal     | 0.99                  | 497,6        | +9.0      | Antiviral therapy | Nasal cannula | MMF and Tac (cessation)    | Recovery |
| 25   | Critical | Cr: 467    | 0.44                  | 44.4         | +9.0      | Antiviral therapy | Nasal cannula | MMF and Tac (cessation)    | Death    |
| 26   | Mild     | Cr: 81.3   | 0.31                  | 76.4         | +9.0      | Antiviral therapy | Nasal cannula | MMF and Tac (cessation)    | Recovery |
| 27   | Critical | Cr: 19.7   | 0.71                  | 57.9         | +9.0      | Antiviral therapy | Nasal cannula | MMF and Tac (cessation)    | Recovery |
| 28   | Mild     | Cr: 97.2   | 0.71                  | 76.4         | +9.0      | Antiviral therapy | Nasal cannula | MMF and Tac (cessation)    | Recovery |
| 29   | Mild     | Cr: 19.7   | 0.71                  | 57.9         | +9.0      | Antiviral therapy | Nasal cannula | MMF and Tac (cessation)    | Recovery |
| 30   | Critical | Cr: 97.2   | 0.71                  | 76.4         | +9.0      | Antiviral therapy | Nasal cannula | MMF and Tac (cessation)    | Recovery |
| 31   | Mild     | Cr: 93.7   | 1.48                  | 48.6         | +9.0      | Antiviral therapy | Nasal cannula | MMF and Tac (cessation)    | Recovery |
| 32   | Critical | Cr: 288.8  | 0.73                  | 35.6         | +9.0      | Antiviral therapy | Nasal cannula | MMF and Tac (cessation)    | Recovery |
| 33   | Severe   | Cr: 72.5   | 0.73                  | 22.6         | +9.0      | Antiviral therapy | Nasal cannula | MMF and Tac (cessation)    | Recovery |
| 34   | Severe   | Cr: 55.7   | 0.72                  | 49.6         | +9.0      | Antiviral therapy | Nasal cannula | MMF and Tac (cessation)    | Recovery |
| 35   | Critical | Cr: 70.7   | 0.71                  | 57.9         | +9.0      | Antiviral therapy | Nasal cannula | MMF and Tac (cessation)    | Recovery |
| 36   | Severe   | Cr: 70.7   | 0.71                  | 57.9         | +9.0      | Antiviral therapy | Nasal cannula | MMF and Tac (cessation)    | Recovery |
| 37   | Severe   | Cr: 138    | 0.61                  | 38.6         | +9.0      | Antiviral therapy | Nasal cannula | MMF and Tac (cessation)    | Recovery |
| 38   | Severe   | Cr: 138    | 0.61                  | 38.6         | +9.0      | Antiviral therapy | Nasal cannula | MMF and Tac (cessation)    | Recovery |
| 39   | Severe   | 150.28     | 0.96                  | 2.9          | +9.0      | Antiviral therapy | Nasal cannula | MMF and Tac (cessation)    | Recovery |
| 40   | Critical | 265.2      | 0.42                  | 8.1          | +9.0      | Antiviral therapy | Nasal cannula | MMF and Tac (cessation)    | Recovery |
| 41   | Severe   | 97.2       | 0.51                  | 6.7          | +9.0      | Antiviral therapy | Nasal cannula | MMF and Tac (cessation)    | Recovery |

Abbreviations: CRP, C-reactive protein; CsA, cyclosporin A; HCQ, hydroxychloroquine; IFN-a, interferon-α; IVIg, intravenous immunoglobulin; MP, methylprednisolone; MPA, mycophenolic acid; mTORi, mTOR inhibitor; Pred, prednisone; Tac, tacrolimus.
3.4 | Novel strategy to classify KTRs with COVID-19 (Type I vs Type II vs Type III vs Type IV)

The KTRs with COVID-19 were classified into four types according to Cr and lymphocyte count as shown in Table 5. We first explored differences among those four types in management of immunosuppression. From Table 5, there was higher mortality in type IV cases than other three types (0 vs 0 vs 0% vs 40%), and all the death cases were included into type IV. Moreover, the mortality in type IV cases treated with approach A was 0/0, approach B was 2/6, and approach C was 4/9 (Table 5).

4 | DISCUSSION

As of July 7, 2020, the total number of confirmed cases of COVID-19 in the world has reached 11.5 million, and the number of daily new cases has not shown a downward trend.27 For the high infectivity of SARS-CoV-2 and the immunosuppressive state, KTRs were more vulnerable to the influence by COVID-19 than general population under the same exposure conditions. The mortality rate of KTRs with COVID-19 was also significantly higher than that of the general population.1 Therefore, we collected such literature and carried out statistical analysis trying to find the reasonable basis for management of immunosuppression.

These data showed that 41 patients we collected were mainly male (75.6%), with a median age of 50 (IQR: 37, 64) years. The initial symptoms were fever, cough, and fatigue, and some patients had digestive system symptoms, like the general population. The severity of patients was divided into mild (41.5%), severe (36.6%), critical (21.9%). The incidence of severe disease was higher than that of the general population.28 Although the mortality rate was 14.6%, <20%-50% in previous reports, it was significantly higher than the general population.29

Although there was no specific drug to fight against COVID-19, taking antiviral drugs and general treatment was the best expedient.
The main antiviral drugs were lopinavir/ ritonavir, HCQ, and umifenovir, and some patients were treated additionally with IVIg (34.1%) and INF-α (9.8%). Previous studies reported that HCQ can effectively fight against SARS-CoV-2, but in the cases we collected, it did not show significant efficacy. In addition, It was reported that lopinavir/ ritonavir could interact with tacrolimus (Tac). Therefore, we should pay close attention to the blood concentration of Tac when giving lopinavir/ritonavir to KTRs, to prevent the occurrence of adverse events caused by high concentration of Tac. Additionally, those cases we collected showed that using IVIg or INF-a did not improve the prognosis of patients. Oxygen therapy was an important measure to improve the patient’s respiratory function. Those cases showed that for mild patients, if they have shortness of breath or dyspnea, nasal cannula should be given; for severe and critical patients, they could be given mechanical ventilation, even extracorporeal membrane oxygenation (ECMO).

There were three immunosuppressive regimens for 41 renal transplant recipients. And the adjustment of immunosuppression was divided into 3 approaches. The results showed that the mortality of approach A was 0, the mortality of approach B was 13.3%, and the mortality of approach C was 22.2%. Further analysis found that the patients treated with approach A were mainly mild patients, indicating that approach A was the best choice for mild cases of KTRs; however, it is too hasty to confirm that approach A applies to all patients.

For the management of immunosuppression for severe and critical cases, we divide patients into four types, as shown in Table 5. Types I and II were mostly mild patients, and therefore, approach A was suitable for those two types of cases. Notably, type II cases suspended antimetabolites, because antimetabolites can significantly inhibit lymphocyte proliferation, and cessation of antimetabolites would help to alleviate peripheral blood lymphocytes depletion. Previous reports showed that after mycophenolate mofetil (MMF) was stopped, the patient who suffered peripheral blood trisystem reduction was eventually cured. Thus, type II cases should apply approach B when they were also classified into severe patients. Types III and IV were mostly severe and critical patients. The reasons for the deterioration of renal function of types III and IV patients were virus invading and inflammatory response in kidney, which induced lymphocytes to aggregate into renal tissue. Therefore, we recommend that immunosuppressive therapy should not be changed for the type III patients, because maintaining on immunosuppressive therapy could mitigate excessive inflammatory response. If type III patients continued to deteriorate, they would become type IV. These patients have respiratory failure, lymphocyte depletion, and renal failure at the same time. The risk of death in type IV patients was very high, and this was the biggest challenge for KTRs infected with SARS-CoV-2. In order to maintain the patient’s life, mechanical ventilation and renal replacement therapy were important measures. At same time, antimetabolites should be stopped due to lymphocyte depletion; CNI and corticosteroids should be maintained against the cytokine storm. Previous studies suggested that only application of corticosteroids in type IV cases could not reverse the patient’s condition.

We summarized the treatment details of 41 patients in the world and concluded a set of immunosuppression adjustment scheme in this article, hoping to provide adjustment basis for clinicians. However, due to the small number of cases, the author’s subjectivity may exist in these reports, which makes our samples biased. Therefore, we call for more clinical reports to focus on the specific adjustment plan of these four types of patients and finally solve the problem of immunosuppressive adjustment.

### ACKNOWLEDGEMENTS

This work was supported by the Medical Science Advancement Program (Clinical Medicine) of Wuhan University [grant numbers: TFLC2018003] and National Science Foundation for Young Scientists of China [grant numbers: 81700657].

### TABLE 5 Novel strategy to classify KTRs with COVID-19

| Parameters                  | Type I (n = 8) | Type II (n = 14) | Type III (n = 4) | Type IV (n = 15) | Death (n) |
|-----------------------------|---------------|------------------|-----------------|-----------------|-----------|
| Classification criteria     |               |                  |                 |                 |           |
| Cr (µmol/L)                | <150          | <150             | ≥150            | ≥150            | -         |
| Lymphocyte (10^9/L)        | ≥0.9          | <0.9             | ≥0.9            | <0.9            | -         |
| Laboratory findings        |               |                  |                 |                 |           |
| CRP (mean, mg/L)           | 48.28         | 56.18            | 62.33           | 67.274          | -         |
| Severity                   |               |                  |                 |                 |           |
| Mild (n)                   | 5             | 8                | 2               | 2               | 0         |
| Severe (n)                 | 3             | 4                | 2               | 6               | 2         |
| Critical (n)               | 0             | 2                | 0               | 7               | 4         |
| Immunosuppression adjustment|              |                  |                 |                 |           |
| Approach A (n)             | 2             | 4                | 2               | 0               | 0         |
| Approach B (n)             | 3             | 5                | 1               | 6               | 2         |
| Approach C (n)             | 3             | 5                | 1               | 9               | 4         |
| Death, n (%)               | 0             | 0                | 0               | 6 (40%)         | -         |
CONFLICT OF INTEREST
The authors declare that they have no conflict of interest.

AUTHOR CONTRIBUTION
HQC and ZZB designed and carried out the research, analyzed the data, and wrote the manuscript. XY, YSJ, and WYF provided guidance and revised the manuscript. YQF designed the experiments, provided overall guidance, and helped to write the manuscript.

ORCID
Qianchao Hu https://orcid.org/0000-0001-5694-7461

REFERENCES
1. Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant. 2020;20(7):1800-1808.
2. Akalin E, Azzi Y, Bartash R, et al. Covid-19 and kidney transplantation. N Engl J Med. 2020;382(25):2475-2477.
3. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-2629.
4. Wang F, Nie J, Wang H, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis. 2020;221(11):1762-1769.
5. Zhong Z, Zhang Q, Xia H, et al. Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients. Am J Transplant. 2020;20(7):1916-1921.
6. Zhu L, Xu X, Ma K, et al. Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression. Am J Transplant. 2020;20(7):1859-1863.
7. Huang J, Lin H, Wu Y, et al. COVID-19 in posttransplant patients—report of 2 cases. Am J Transplant. 2020;20(7):1879-1881.
8. Wang J, Li X, Cao G, Wu X, Wang Z, Yan T. COVID-19 in a kidney transplant patient. Eur Urol. 2020;77(6):769-770.
9. Marx D, Moulin B, Fati-Kremer S, et al. First case of COVID-19 in a kidney transplant recipient treated with belatacept. Am J Transplant. 2020;20(7):1944-1946.
10. Bartiromo M, Borchi B, Botta A, et al. Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19). Transpl Infect Dis. 2020;e13286. https://doi.org/10.1111/tid.13286
11. Zhang H, Chen Y, Yuan Q, et al. Identification of kidney transplant recipients with coronavirus disease 2019. Eur Urol. 2020;77(6):742-747.
12. Chen S, Yin Q, Shi H, et al. A familial cluster, including a kidney transplant recipient, of coronavirus disease 2019 (COVID-19) in Wuhan, China. Am J Transplant. 2020;20(7):1869-1874.
13. Seminari E, Colaneri M, Sambo M, et al. SARS CoV2 infection in a renal transplanted patients. A case report. Am J Transplant. Published online April 3, 2020;20(2):1882-1884. https://doi.org/10.1111/ajt.15902
14. Fernández-Ruiz M, Andrés A, Loinaz C, et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am J Transplant. 2020;20(7):1849-1858.
15. Arpali E, Akyollu B, Yelken B, Tekin S, Turkmen A, Kocak B. Case report: a kidney transplant patient with mild COVID-19. Transpl Infect Dis. 2020;e13296. https://doi.org/10.1111/tid.13296
16. Bussalino E, De Maria A, Russo R, Paolletti E. Immunosuppressive therapy maintenance in a kidney transplant recipient SARS-CoV-2 pneumonia: a case report. Am J Transplant. 2020;20(7):1922-1924.
17. Ning L, Liu L, Li W, et al. Novel coronavirus (SARS-CoV-2) infection in a renal transplant recipient: case report. Am J Transplant. 2020;20(7):1864-1868.
18. Zhu L, Gong N, Liu B, et al. Coronavirus disease 2019 pneumonia in immunosuppressed renal transplant recipients: a summary of 10 confirmed cases in Wuhan, China. Eur Urol. 2020;77(6):748-754.
19. Kates OS, Fisher CE, Stankiewicz-Karita HC, et al. Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients in the United States. Am J Transplant. 2020;20(7):1885-1890.
20. Kocak B, Arpali E, Akyollu B, et al. Oligosymptomatic kidney transplant patients with COVID-19: do they pose a risk to other recipients? Transpl Proc. 2020;1–4. https://doi.org/10.1016/j.transproceed.2020.05.028
21. Fung M, Chiu CY, DeVoe C, et al. Clinical outcomes and serologic response in solid organ transplant recipients with COVID-19: a case series from the United States. Am J Transplant. 2020;1–9. https://doi.org/10.1111/ajt.16079
22. Cheng DR, Wen JQ, Liu ZZ, Lv TF, Chen JS. Coronavirus disease 2019 in renal transplant recipients: report of two cases. Transpl Infect Dis. 2020;e13329. https://doi.org/10.1111/tid.13329
23. Tantisattamo E, Reddy UG, Duong DK, et al. Hypnotremia: a possible immuno-neuroendocrine interface with COVID-19 in a kidney transplant recipient. Transpl Infect Dis. 2020;e13355. https://doi.org/10.1111/tid.13355
24. Chen D, Yang B, Zhang Y, et al. Withdrawing mycophenolate mofetil in treating a young kidney transplant recipient with COVID-19: a case report. Medicine (Baltimore). 2020;99(24):e20481.
25. Maritati F, Cerutti E, Zuccatosta L, et al. SARS-CoV-2 infection in kidney transplant recipients: experience of the italian marche region. Transpl Infect Dis. 2020;e13377. https://doi.org/10.1111/tid.13377
26. China NHCo. New coronavirus pneumonia prevention and control program (7th). http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4ce80dc75f912eb1989/files/ce3e6945832a438eaae415350a8ce964.pdf. Accessed March 30, 2020.
27. WHO. Coronavirus disease (COVID-19) Dashboard—Data last updated: 2020/7/7, 2:34pm CEST. https://covid19.who.int/. Accessed July 7, 2020.
28. Guan W-J, Ni ZY, Hu YU, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.
29. Wang D, Hu BO, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1068.
30. Meo SA, Klonoff DC, Akram J. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. Eur Rev Med Pharmacol Sci. 2020;24(8):4539-4547.

How to cite this article: Hu Q, Zhong Z, Xiong Y, Ye S, Wang Y, Ye Q. Management of immunosuppression in kidney transplant recipients with COVID-19 pneumonia: A summary of 41 confirmed cases reported worldwide. Transpl Infect Dis. 2021;23:e13425. https://doi.org/10.1111/tid.13425